Nanostructured lipid carriers based temozolomide and gene co-encapsulated nanomedicine for gliomatosis cerebri combination therapy

Figures & data

Table 1. NLCs composition.

Lipid phase	888 ATO/Cremophor ELP/SPC	Soya lecithin	TMZ
Amount (mg)	200/100/100	100	100
Aqueous phase	DNA	Tween-80	DDAB
Amount (mg)	100	20	10

Table 2. Characterization of different vectors.

Formulations	Blank NLCs	DNA-NLCs	TMZ-NLCs	TMZ/ DNA-NLCs
Particle size  (nm)	70.2 ± 1.6	145.2 ± 1.6	153.5 ± 1.9	178.9 ± 2.7
Size distribution  (PDI)	0.11 ± 0.03	0.13 ± 0.02	0.15 ± 0.04	0.16 ± 0.05
Zeta potential  (mV)	+48.6 ± 4.1	+33.1 ± 3.9	+40.6 ± 3.5	+22.8 ± 2.8
GL (%)	N/A	N/A	91.9 ± 1.7	90.8 ± 1.5
EE (%)	N/A	85.4 ± 3.2	80.5 ± 2.8	82.7 ± 2.5

Figure 1. Cell viability of different vectors at various concentrations.

Figure 2. Flow cytometric analysis of EGFP positive U87 MG cells.

Figure 3. In vivo anticancer efficiency of different formulations.